Impact of antibiotic restrictions: The ethical perspective

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 5, 2006, Pages 16-24

  Garau, J ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Antibiotic resistance; Ethics; Optimal antibiotic prescribing; Rational antibiotic prescribing; Review

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AWARENESS; BACTERIAL INFECTION; BENEFICENCE; COMMUNITY ACQUIRED PNEUMONIA; CONFLICT OF INTEREST; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG USE; ERADICATION THERAPY; EXPECTATION; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL INFORMATION; MINIMUM INHIBITORY CONCENTRATION; PATIENT ATTITUDE; PATIENT AUTONOMY; PERSONNEL MANAGEMENT; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PUNISHMENT; REVIEW; RISK BENEFIT ANALYSIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WELFARE;

BACTERIA (MICROORGANISMS);

EID: 33745267244     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01527.x     Document Type: Review

References (35)

1. Gerding DN, Martone WJ. SHEA conference on antimicrobial resistance. Society for Healthcare Epidemiology of America. Infect Control Hospital Epidemiol 2000; 21: 347-351.
2. Centers for Disease Control. Antimicrobial Resistance Interagency Task Force 2003 Annual Report. Atlanta: Centers for Disease Control, 2003.
3. European Community. Council Resolution of 8 June, 1999 on antibiotic resistance; a strategy against the microbial threat. Official Journal of the European Community 1999; 195: 1-3.
4. Orr RD, Pang N, Pellegrino ED, Siegler M. Use of the Hippocratic Oath: A review of twentieth century practice and a content analysis of oaths administered in medical schools in the U.S. and Canada in 1993. J Clin Ethics 1997; 8: 377-388.
5. Metlay JP, Shea JA, Crossette LB, Asch DA. Tensions in antibiotic prescribing: Pitting social concerns against the interests of individual patients. J Gen Intern Med 2002; 17: 87-94.
6. Metlay JP, Shea JA, Asch DA. Antibiotic prescribing decisions of generalists and infectious disease specialists: Thresholds for adopting new drug therapies. Med Decis Making 2002; 22: 498-505.
7. Price DB, Honeybourne D, Little P et al. Community-acquired pneumonia mortality: A potential link to antibiotic prescribing trends in general practice. Respir Med 2004; 98: 17-24.
8. Morrissey I, McKeon M, Dowling K, Colclough A, Viljoen L, Veltman T. TARGET surveillance, a part of the LIBRA initiative: Comparative activity of moxifloxacin against respiratory pathogens isolated during 2003 [Abstract P1790]. Clin Microbiol Infect 2005; 11 (Suppl. 2).
9. Garau J. Why do we need to eradicate pathogens in respiratory tract infections? Int J Infect Dis 2003; 7 (Suppl. 1): S5-S12.
10. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: The case of macrolides. J Antimicrob Chemother 2002; 50 (Suppl. S2): 87-92.
11. Depardieu F, Courvalin P. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 319-323.
12. Kays MB, Wack MF, Smith DW, Denys GA. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002; 43: 163-165.
13. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.
14. Perez-Trallero E, Marimon JM, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9: 1159-1162.
15. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.
16. Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Management of fluoroquinolone resistance in Pseudomonas aeruginosa - outcome of monitored use in a referral hospital. Int J Antimicrob Agents 1998; 10: 207-214.
17. Rifenburg RP, Paladino JA, Bhavnani SM, Haese DD, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm 1999; 56: 2217-2223.
18. Bhavnani SM, Callen WA, Forrest A et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals. Am J Health Syst Pharm 2003; 60: 1962-1970.
19. Iannini PB, Tillotson GS. Impact of quinolone substitution on Pseudomonas aeruginosa resistance, antimicrobial usage and hospital costs. Pharmacotherapy 2001; 21 (Suppl.): 371.
20. Peterson L. Stability of antimicrobial activity against emerging resistance in Gram-negative pathogens recovered from hospitalized patients [abstract 11.029]. 10th International Congress on Infectious Diseases, Hong Kong, 11-14. March 2002. Boston: International Congress of Infectious Diseases, 2002.
21. Zambrano CH, Postelnik MJ, Noskin GA. Relationship between antimicrobial usage and susceptibility in specific patient care areas: A 3-year assessment [abstract 496]. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, 25-28 October 2001. Alexandria: Infectious Diseases Society of America, 2001.
22. Hill HA, Haber MJ, McGowan JE et al. A link between quinolone use and resistance in P. aeruginosa ? [abstract 495] 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, 25-28 October 2001. Alexandria: Infectious Diseases Society of America, 2001.
23. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Infect Dis 2001; 32: 701-707.
24. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
25. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005; 51: 31-37.
26. Horn SD. Unintended consequences of drug formularies. Am J Health Syst Pharm 1996; 53: 2204-2206.
27. Beilby J, Marley J, Walker D, Chamberlain N, Burke M. Effect of changes in antibiotic prescribing on patient outcomes in a community setting: A natural experiment in Australia. Clin Infect Dis 2002; 34: 55-64.
28. Hensley PL, Nurnberg HG. Formulary restriction of selective serotonin reuptake inhibitors for depression: Potential pitfalls. Pharmacoeconomics 2001; 19: 973-982.
29. Paladino JA. Economic justification of antimicrobial management programs: Implications of antimicrobial resistance. Am J Health Syst Pharm 2000; 57 (Suppl. 2): S10-S12.
30. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
31. Buising KL, Thursky KA, Black JF, Brown GV. Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)? Med J Aust 2004; 180: 486-487.
32. Niederman MS. What is the prognosis for using the pneumonia severity index to make site-of-care decisions in community-acquired pneumonia? Chest 2003; 124: 2051-2053.
33. Burck R. Minimal risk: The debate goes on. Crit Care Med 2002; 30: 1180-1.
34. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
35. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24: 639-652.